Holmusk, a Singapore-based data science and health technology company, raised US$21.5m in funding.
The round was led by Optum Ventures and Health Catalyst Capital with participation from existing investors Heritas Capital and other individuals. In conjunction with the funding, Dr. Vijay Barathan from Optum Ventures (OV) and Charles Boorady from Health Catalyst Capital (HCC) will be joining the Board of Directors.
The company intends to use the funds to expand its US operations in New York City and invest in its proprietary technology to harness and analyze real-world data to accelerate drug development and data-driven medicine.
Founded in 2015, Holmusk is building a large Real-World Evidence (RWE) platform in behavioral health and chronic diseases which aims to expand data-driven, evidence-based care for people managing behavioral health conditions. This is made possible by bringing together specialty behavioral health data and its novel analytics platform to deliver evidence-based insight that care providers, health care payers and patients can use to make informed care and treatment decisions, and integrate care for people with both behavioral and chronic health needs. These capabilities can also aid pharma companies with R&D and commercialization of new drugs.
The company has offices in New York City, London and Shanghai.